Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas

Simple item page
dc.coverageDOI: 10.3390/ijms24010478
dc.creatorGonzález-Arriagada, Wilfredo Alejandro
dc.creatorGarcía, Isaac E.
dc.creatorMartínez-Flores, René
dc.creatorMorales-Pison, Sebastián
dc.creatorColetta, Ricardo D.
dc.date2022
dc.date.accessioned2026-01-05T21:13:31Z
dc.date.available2026-01-05T21:13:31Z
dc.description<p>The interaction between malignant cells and the tumor microenvironment is critical for tumor progression, and the chemokine ligand/receptor axes play a crucial role in this process. The CXCR4/CXCL12 and CCR5/CCL5 axes, both related to HIV, have been associated with the early (epithelial–mesenchymal transition and invasion) and late events (migration and metastasis) of cancer progression. In addition, these axes can also modulate the immune response against tumors. Thus, antagonists against the receptors of these axes have been proposed in cancer therapy. Although preclinical studies have shown promising results, clinical trials are needed to include these drugs in the oncological treatment protocols. New alternatives for these antagonists, such as dual CXCR4/CCR5 antagonists or combined therapy in association with immunotherapy, need to be studied in cancer therapy.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/f04f8176-dc65-4a4b-91aa-d21533f751ef
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/65708
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.24 (2022) date: 2022-12-28 nr.1 p.1-12
dc.subjectcancer therapy
dc.subjectchemokines
dc.subjectimmunotherapy
dc.subjectoncology
dc.subjectSDG 3 - Good Health and Well-being
dc.titleTherapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomaseng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
Pure-CRIS